Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”: 
Via Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors. 
Via The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners. 
Via InvestorPlace
Analyst Ratings for Reata Pharmaceuticals
Via Benzinga
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals
Via Benzinga
Expert Ratings for Reata Pharmaceuticals
Via Benzinga
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
With an Acquisition on the Way, Is Biogen Stock a Buy?
Can the biotech finally get back in the good graces of investors? 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023
Via Benzinga
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
Biogen also recently announced a plan to cut costs and focus investment on high-growth areas. 
Via The Motley Fool
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
Crude Oil Edges Higher; Colgate-Palmolive Posts Upbeat Earnings
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Friday. The Dow traded up 0.42% to 35,432.07 while the NASDAQ rose 1.79% to 14,301.74. The... 
Via Benzinga
Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review
Despite Thursday's downside reversal, the major indexes had a solid advance. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Avantor Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday. 
Via Benzinga
Dow Surges 250 Points; Exxon Mobil Earnings Miss Expectations
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0.72% to 35,535.23 while the NASDAQ rose 1.89% to 14,316.53. The S&P 500,... 
Via Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
Skechers, Chart Industries, Roku, Beazer Homes And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) rose... 
Via Benzinga
Why Is QuantumScape (QS) Stock Up 10% Today?
QuantumScape (QS) stock is continuing to rally on Friday following an update from its latest earnings report and EV battery plans. 
Via InvestorPlace
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB). 
Via InvestorPlace
Nasdaq Jumps 200 Points; Procter & Gamble Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.39% to 35,419.43 while the NASDAQ rose... 
Via Benzinga
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals
Reata stock surged more than 50% on the news. 
Via Investor's Business Daily
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.